In 2017 there were an estimated 322,000 drug treatable patients worldwide with Metastatic Castrate Resistant Prostate Cancer.
Over the next decade, growth in the number of first-line cases will increase across lower income countries with 40% growth, versus high income countries with 14% growth.
This growth is driven by both increased diagnoses in these countries as well as aging and growing populations in these markets.
How will you help patients access innovative therapies in these high-need growth markets over the next decade?
Contact us to uncover the complete landscape for a disease and learn how you can size global markets with real-world data.